Number of the records: 1
Glyoxalase I Glu111Ala Polymorphism in Patients with Breast Cancer
- 1.
SYSNO ASEP 0332958 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Glyoxalase I Glu111Ala Polymorphism in Patients with Breast Cancer Title Glyoxalase I Glu111Ala polymofismus u pacientů s rakovinou prsu Author(s) Germanová, Al. (CZ)
Germanová, A. (CZ)
Tesarová, P. (CZ)
Jáchymová, M. (CZ)
Zvára, Karel (UIVT-O)
Zima, T. (CZ)
Kalousová, M. (CZ)Source Title Cancer Investigation. - : Taylor & Francis - ISSN 0735-7907
Roč. 27, č. 6 (2009), s. 655-660Number of pages 6 s. Language eng - English Country US - United States Keywords glyoxalase I ; advanced glycation end products ; breast cancer Subject RIV BB - Applied Statistics, Operational Research CEZ AV0Z10300504 - UIVT-O (2005-2011) UT WOS 000267370700009 DOI 10.1080/07357900802350822 Annotation Effect of advanced glycation end products (AGEs) in the pathogenesis of cancer could be diminished by interaction with soluable RAGE or by reducing AGE-precusors via glyoxalase I. Glu111Ala polymorphism of glyoxalaseI gene, AGEs, and sRAGE serum levels were studied in 113 breast cancer patients and in 58 controls. Higher frequency of the mutated C allele was found in patients with negative estrogen receptors and in patients in clinical stage III compared to controls (P<0.05). The presence of the C allele could represent a negative prognostic factor; however, further studies are needed to confirm this hypothesis. Workplace Institute of Computer Science Contact Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Year of Publishing 2010
Number of the records: 1